Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
- Conditions
- Esophageal CancerAdvanced or Metastatic Solid Tumors with a SMARCA4 Mutationnon-small cell lung cancer (NSCLC)
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Prelude Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- 2024-516889-11-00
- Locations
- 🇩🇪
Goethe University Frankfurt, Frankfurt Am Main, Germany
🇪🇸Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
🇪🇸Hospital Quironsalud Barcelona, Barcelona, Spain
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- Conditions
- Metastatic Solid TumorAdvanced Solid TumorNon-small Cell Lung CarcinomaSMARCA4 Mutation
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 104
- Registration Number
- NCT06560645
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)Diffuse Large B-cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)MDS/Myeloproliferative Neoplasm (MPN) Overlap SyndromeRichter's SyndromeT-cell LymphomaChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 86
- Registration Number
- NCT05665530
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
- Conditions
- Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutation
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05639751
- Locations
- 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
🇺🇸Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Breast CancerGlioblastomaHead and Neck Squamous Cell CarcinomaNon-small Cell Lung CancersMalignant MesotheliomaSarcomaEndometrial Cancer
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT05538572
- Locations
- 🇺🇸
Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
🇺🇸AdventHealth Medical Group Oncology Research at Celebration, Celebration, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Prelude Therapeutics' PRT3789 Shows Promise in SMARCA4-Mutated Cancers
• Prelude Therapeutics' PRT3789 demonstrated anti-tumor activity in SMARCA4-mutated NSCLC and esophageal cancer patients during Phase 1 dose escalation. • The Phase 1 trial of PRT3789 showed the drug was generally well-tolerated, with no dose-limiting toxicities or study drug-related serious adverse events. • The company aims to confirm the biologically active dose of PRT3789 by year-end and advance monotherapy and docetaxel combination studies. • Preclinical data suggests that dual SMARCA2/4 degraders attached to antibodies could expand treatment possibilities beyond SMARCA4 mutations.